ANO1 and cancer: These results suggest that the slow downregulation of ANO1 may be more beneficial in the treatment of cancer patients because it may exhibit anticancer activity without significant changes in blood pressure and gastrointestinal motility by providing sufficient time to compensate for the decreased ANO1 channel activity.